Anaptysbio (ANAB) Appoints Daniel Faga to its Board

November 29, 2021 4:06 PM EST
Get Alerts ANAB Hot Sheet
Price: $31.28 +4.30%

Overall Analyst Rating:
    NEUTRAL (Up Up)

Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Mr. Daniel Faga to the company’s Board of Directors.

“Dan has extensive corporate strategy, finance and public company leadership experience in building world-class biopharmaceutical companies,” said Hamza Suria, president and chief executive officer of AnaptysBio. “His unique strategic vision is an exciting addition to our Board of Directors and we look forward to having Dan’s perspective as AnaptysBio continues to advance multiple wholly-owned clinical and preclinical first-in-class therapeutic antibody programs.”

Mr. Faga commented, “AnaptysBio has an impressive track-record of innovating novel therapeutics and is financially well-positioned to drive potentially transformative medicines over the next several years. I am excited about AnaptysBio’s future enabled by the strategic optionality of the company’s pipeline and look forward to working with the Board and management team.”

Mr. Faga is a seasoned executive with more than 20 years of industry and advisory experience in the life sciences industry. Most recently, he was the chief operating officer at Mirati Therapeutics responsible for leading the company’s strategy, corporate finance, legal and other business operations. Prior to Mirati, Dan was chief business officer at Spark Therapeutics until its acquisition by Roche. Previously, Dan was a managing director and founding member of Centerview Partner’s healthcare advisory practice. Dan’s earlier experience includes healthcare investment banking at Merrill Lynch and management consulting in the life sciences practice at PRTM. Dan has earned a B.S. in engineering from Cornell University and an M.B.A. in healthcare management from the Wharton School of the University of Pennsylvania.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Board Changes, Corporate News

Related Entities

Definitive Agreement, BofA/Merrill Lynch